CT-996
Phase 1 Study of CT-996 in Overweight/Obese Participants and Patients With Type 2 Diabetes Mellitus
Carmot Australia First Pty Ltd · Phase 1 · Completed · Enrollment 94
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Part 1: CT-996 SAD Cohort 1 | Obesity + T2D | n/r | n/r | n/r | n/r |
| Part 1: CT-996 SAD Cohort 2 | Obesity + T2D | n/r | n/r | n/r | n/r |
| Part 1: CT-996 SAD Cohort 3, Then SAD Cohort 5 | Obesity + T2D | n/r | n/r | n/r | n/r |
| Part 1: CT-996 SAD Cohort 4 | Obesity + T2D | n/r | n/r | n/r | n/r |
| Part 1: CT-996 SAD Cohort 6 | Obesity + T2D | n/r | n/r | n/r | n/r |
| Part 1: Placebo SAD Cohort | Obesity + T2D | n/r | n/r | n/r | n/r |
| Part 2: CT-996 MAD Cohort 1 | Obesity + T2D | n/r | n/r | n/r | n/r |
| Part 2: CT-996 MAD Cohort 2 | Obesity + T2D | n/r | n/r | n/r | n/r |
| Part 2: CT-996 MAD Cohort 3 | Obesity + T2D | n/r | n/r | n/r | n/r |
| Part 2: Placebo MAD Cohort | Obesity + T2D | n/r | n/r | n/r | n/r |
| Part 3: CT-996 MD T2DM Cohort 1 | Obesity + T2D | n/r | n/r | n/r | n/r |
| Part 3: CT-996 MD T2DM Cohort 2 | Obesity + T2D | n/r | n/r | n/r | n/r |
| Part 3: Placebo MD T2DM Cohort | Obesity + T2D | n/r | n/r | n/r | n/r |